

NIH Research Performance Progress Report

Directions for University of Maryland Contact your Contract Administrator with any questions.

Special thanks to Dr. Goupell for assistance in creating these materials.

Table of Contents

Ger	nera	l Notes	3
	A.	Cover Page	5
	B.	Accomplishments	6
	C.	Products	9
	D.	Participants	11
	E.	Impact	14
	F.	Changes	15
	G.	Special Reporting Requirements	17
	Н.	Budget	21
Complete and Submit 22			22

The RPPR will replace the eSNAP tool in NIH eRA Commons. More detailed instructions can be found at http://grants.nih.gov/grants/rppr/rppr instruction guide.pdf.

General notes:

The use of the RPPR Module for submitting Streamlined Noncompeting Award Process (SNAP) and Fellowship progress reports will be required for awards with start dates on or after July 1, 2013 (i.e., due dates on or after May 15, 2013, for SNAP awards and May 1, 2013, for Fellowships). The functionality of the RPPR is also expanding on April 18, 2013 to include requests from the awarding Institutes and Centers (ICs) for additional materials following submission of an RPPR and electronic submission of the additional materials by the grantee. Either a RPPR or eSNAP may be submitted during the early access phase, but not both. Attachments to the RPPR must be in PDF format and any data fields/text boxes must be completed with ASCCII characters only.

UM delegates the authority to submit RPPRs and eSNAPs to the PD/PI. These reports do not need to be routed to your Contract Administrator for submission in NIH eRA Commons unless there is a reduction in the level of effort of any senior/key person by 25% or more as documented in D.2 Personnel Updates. In this case, the RPPR must be routed to the Contract Administrator for approval and submission.

For applications with multiple PD/PIs (MPI applications), only the Contact PD/PI has access to the Edit feature unless the Contact PD/PI has granted progress report authority to other PD/PIs. Without this authority, MPIs can only view the RPPR PDF and its routing history.


Depending on the type of award, the required content of the RPPR may vary.

Accessing the RPPR


Log into Commons.

Select the eSNAP menu.

Select the Grant Number link for the Award.




Select RPPR.



Click on Initiate to begin the RPPR.

Once you have initiated the process, select Edit to begin to enter data.



The RPPR consists of 8 sections.

A: Cover Page E. Impact B. Accomplishments F. Changes

C. Products G. Special Reporting Requirements

D. Participants H. Budget

Complete each section and SAVE before moving on to the next section.

Once complete, click on Manage eSNAP.

Click on the Check for Errors button. If there are any errors, they must be corrected. Be certain to save the changes. Once there are no more errors, click the Route button to route to Contact Administrator in ORA (only required if 25% or more reduction of effort for Senior/Key Personnel) or Submit to submit directly to NIH.

More detailed instructions can be found at http://grants.nih.gov/grants/rppr/rppr instruction guide.pdf.









A. Cover Page:

Confirm Data.


Add Signing Official and Administrative Official – select ORA Contract Administrator and Assistant Director for drop down lists.

Recipient ID can be left blank.


A. Cover Pa	ge 🔞				
Save Cancel					
	Grant Information		μ	A.4 Recipient Organization	Information
Grant Number:	5R00DC010206-04	Organization Na	ame:	UNIVERSITY OF MARYLAND	COLLEGE PK CAMPUS
Project Title:	Speech understanding and signal detection in noise in bilateral cochlear implants	Address:		Office of Research Administra 3112 LEE BUILDING COLLEGE PARK MD 2074251	
A.1	Program Director/Principal Investigator (PD/PI) Information 😲	DUNS:		790934285	
Name:	GOUPELL, MATTHEW J	EIN:		1520710851A1	
E-mail:		Recipient ID: 🕜			
Phone:					
_	e of contact PD/PI on a multiple-PI award? N/A Yes No ne eRA Commons ID of the new contact PD/PI	Start Date: 0	9/03/2011	Project/Grant Perion	e: 08/31/2014
	A.2 Signing Official Information	Start Date: 0	9/03/2011	End Dat	
Name:	STERN, LAUREN ▼	Start Date. 0	1910312011	End Dat	e. 00/3/1/20/12
E-mail:	lcstern@umd.edu			Requested Budget Po	eriod
Phone:		Start Date: 0	9/01/2012	End Dat	e: 08/31/2013
	A.3 Administrative Official Information	Report Frequency:	Annual	Other Frequer	ecy:
Name:	CRIERIE, EVAN LEIGH ▼				
E-mail:	ecrierie@umd.edu				
Phone:	3014056273				
Save Cancel	A Cover Page B Accomplishments C Products D Participants E Impact F Change	ies <u>G Special Reporti</u>	ng Reg <u>H Bu</u>	<u>idqet</u>	

B. Accomplishments


B. 1 Major goals: list goals/specific aims as stated in the approved application. Significant changes in objectives and scope require prior approval of agency. Major goals must be provided in the initial RPPR and will pre-populate in subsequent reports. Goals may be amended by answering Yes to B.1.a.




B.2. Upload a PDF attachment listing accomplishments towards goals. (PDF file name must not contain spaces or special characters.)



B. 3. If Revision or Supplement has been submitted for the award, answer Yes and complete data. For more than one Revision or Supplement, click on Add New.



B.4 Training and Professional Development. Select Nothing to Report or upload PDF listing training and professional development opportunities. (PDF file name must not contain spaces or special characters.)



B.5 Dissemination of results. Select nothing to report or add text as to how results have been disseminated (max 8000 characters; NIH recommends 1 page length).

B.5 How have the results been disseminated to communities of interest?		
Describe how the results have been disseminated to communities of interest. Include any outreach activities that have been undertaken to reach members of communities who are not usually aware of these research activities, for the purpose of enhancing public understanding and increasing interest in learning and careers in science, technology, and the humanities.		
Reporting the routine dissemination of information (e.g., websites, press releases) is not required. For awards not designed to disseminate information to the public or conduct similar outreach activities, a response is not required and the grantee should select "Nothing to Report". A detailed response is only required for awards or award components that are designed to disseminate information to the public or conduct similar outreach activities. Note that scientific publications and the sharing of research sources will be reported under Products.		
Nothing to Report		
or enter response below (NIH recommended length is up to 1 page. Limit is 8000 characters or approximately 3 pages.)		

B.6 Next reporting period.

Add text as to plans for next reporting period (max 8000 characters; NIH recommends 1 page length). Significant changes in objectives and scope require prior approval of the agency.

B.6 What do you plan to do during the next reporting period to accomplish the goals?		
Describe briefly what you plan to do during the next reporting period to accomplish the goals and objectives.		
Remember that significant changes in objectives and scope require prior approval of the agency (e.g., NIH Grants Policy Statement, 8.1.2.).		
Include any important modifications to the original plans. Provide a scientific justification for any changes involving research with human subjects or vertebrate animals. A detailed description of such changes must be provided under Changes.		
Enter response below (NIH recommended length is up to 1 page. Limit is 8000 characters or approximately 3 pages.)		
Total remaining allowed limit is 8000 characters.		
Save Cancel A Cover Page B Accomplishments C Products D Participants E Impact F Changes G Special Reporting Reg H Budget		


C. Products

C.1. Publications: PD/PIs are required to report all publications that arise from their NIH award in this section.

If there are no publications to report, select No.

Publications listed in other parts of the RPPR will not be tracked as award products. Table is pre-populated with My NCBI account information. Select products to be associated with this progress report.

More information on My NCBI: http://www.ncbi.nlm.nih.gov/books/NBK3842/#MyNCBI.Getting Started



C.2. Websites

Select Nothing to Report, or list URLs that disseminate the results of the research activities.

C.2 Website(s) or other Internet site(s)			
List the URL for any Internet site(s) that disseminates the results of the research activities. A short description of each site should be provided. It is not necessary to include the publications already specified above.			
For awards not designed to create or maintain one or more websites select "Nothing to Report". A description is only required for awards designed to create or maintain one or more websites. Limit the response to this reporting period.			
Nothing to Report			
or list URL(s) for Internet site(s) and provide description(s) below (NIH recommended length is up to 1 page. Limit is 8000 characters or approximately 3 pages.)			
.ii			
Total remaining allowed limit is 8000 characters.			

C.3. Technologies

Select Nothing to Report, or list technologies that have resulted from the research activities.

.3 Technologies or techniques	
lentify technologies or techniques that have resulted from the research activities. Describe the technologies or techniques and how they are being shared. 🚁 Limit the response to this reporting period.	
Nothing to Report	
r identify and describe technologies or techniques below (NIH recommended length is up to 1 page. Limit is 8000 characters or approximately 3 pages.)	
	.::
otal remaining allowed limit is 8000 characters.	- 1

C.4 Inventions

Answer questions about inventions.

C.4 Inventions, patent applications, and/or licenses
Have inventions, patent applications and/or licenses resulted from the award during this reporting period? O Yes O No
If yes, has this information been previously provided to the PHS or to the official responsible for patent matters at the grantee organization? 🔘 Yes 🔘 No
Reporting of inventions through iEdison is strongly encouraged. <u>iEdison</u>

C. 5. Other Products and Resource Sharing

Select Nothing to Report or upload PDF response. (PDF file name must not contain spaces or special characters.)

C.5 Other products and resource sharing		
C.5.a Other Products dentify any other significant products that were developed under this project.		
Describe the product and how it is available to be shared with the research community. Do not repeat information provided above. Limit the response to this reporting period.		
Examples of other products are: audio or video products; data and research material (e.g., cell lines, DNA probes, animal models); databases; educational aids or curricula; instruments or equipment; models; protocols; and software or netware.		
Nothing to Report or upload Response Add Attachment Delete Attachment View Attachment		
C.5.b Resource sharing ?		
If the initial research plan addressed, or the terms of award require, a formal plan for sharing final research data, model organisms, Genome Wide Association Studies data, or other such project-specific data, describe the progress in implementing that plan. For sharing model organisms, include information on the number of requests received and number of requests fulfilled during this reporting period. If the sharing plan is fully implemented, provide a final statement on data sharing.		
□ Nothing to Report		
or upload Response Add Attachment Delete Attachment View Attachment View Attachment		
Save Cancel Cover Page Accomplishments Products Participants Impact Changes Special Reporting Reg Budget		


D. Participants

Provide information for PD/PI and each person who has worked at least 1 person month on the project.

To add person months for PI, select Edit next to PI name and edit information. Click Add/New to commit these changes and then Save.

Click Add New to add other individuals as needed.


Enter in Commons ID for other individuals to populate information from his/her Commons profile. Indicate the nearest whole person month (Calendar, Academic, Summer) that the individual worked on the project.



D.2.a Level of Effort

Answer question and provide explanation.

If there is a reduction of effort of any senior/key person by 25% or more the PD/PI must route this RPPR to ORA for approval and submission to NIH eRA Commons.



D.2.b New Senior/Key Personnel

Answer question and upload biosketch for individual. This field will accept only 1 attachment, for multiple new senior/key personnel, combine the PDFs outside of Commons and upload together.

D.2c-e

Answer questions and upload attachment as needed. Attachments must be in PDF format; PDF file name must not contain spaces or special characters.


D.2.b New Senior/Key Personnel		
Are there, or will there be, new senior/key personnel? Yes No		
Senior/key personnel are those identified by the grantee institution as individuals who contribute in a substantive measurable way to the scientific development or execution of the project, whether or not salaries are requested. Typically these individuals have doctoral or other professional degrees, although individuals at the masters or baccalaureate level may be considered senior/key personnel if their involvement meets this definition. Consultants may be considered senior/key personnel if they meet this definition. "Zero percent" effort or "as needed" is not an acceptable level of involvement for senior/key personnel.		
If yes, upload biosketches and other support for all new senior/key personnel 🚱		
Add Attachment Delete Attachment View Attachment		
D.2.c Changes in Other Support 🕝		
Has there been a change in the active other support of senior/key personnel since the last reporting period? Yes No		
If yes, upload active other support for senior/key personnel whose support has changed and indicate what the change has been		
Add Attachment Delete Attachment View Attachment		
D.2.d New Other Significant Contributors		
Are there, or will there be, new other significant contributors? O Yes No		
Other significant contributors are individuals who have committed to contribute to the scientific development or execution of the project, but are not committing any specified measurable effort (i.e., person months) to the project.		
If yes, upload biosketches for all new other significant contributors		
Add Attachment Delete Attachment View Attachment		
<u>l</u>		



E. Impact

Section E Impact will be used to describe ways in which the work, findings, and specific products of the project have had an impact during this reporting period.

- E1 Not applicable for most awards.
- E2 Impact on infrastructure resources Select nothing to report or add text of description. Limit of 8000 characters, NIH recommends 1 page.
- E3. Not applicable for most awards
- E4. Award budget spent in foreign countries. Select nothing to report, or add dollar amount and country. Click Add New to add additional lines.



F. Changes

The RPPR Section F addresses Changes. Grantees are reminded that significant changes in objectives and scope require prior approval of the agency.

- F1 Not applicable for most awards.
- F.2. Challenges Select nothing to report or add text of description. Limit of 8000 characters, NIH recommends 1 page.

F.1 Not Applicable F.2 Actual or anticipated challenges or delays and actions or plans to resolve them Describe challenges or delays encountered during the reporting period and actions or plans to resolve them. Describe only significant challenges that may impede the research (e.g., accrual of patients, hiring of personnel, need for resources or research tools) and emphasize their resolution. Nothing to Report or describe challenges or delays and plans to resolve them below (NIH recommended length is up to 1 page. Limit is 8000 characters or approximately 3 pages.)

F. 3a-d

Changes to Human Subjects, Vertebrate Animals, Biohazards, and/or Select Agents Select no change or add attachment as needed. Attachments must be in PDF format; PDF file name must not contain spaces or special characters.


F.3.a Human Subjects		
If human subject protocols are or will be different from the previous submission, include a description and explanation of how the protocols differ and provide a new or revised Protection of Human Subjects Section as described in the competing application instructions.		
No Change or upload description of change Add Attachment Delete Attachment View Attachment View Attachment		
F.3.b Vertebrate Animals		
If there are or will be significant changes to the uses of vertebrate animals from the previous submission, provide a description of the changes. Examples of changes considered to be significant include, but are not limited to, changing animal species, changing from noninvasive to invasive procedures, new project/performance site(s) where animals will be used, etc. If studies involving live vertebrate animals are planned and were not part of the originally proposed research design, provide a new or revised Vertebrate Animal Section as described in the competing application instructions.		
No Change or upload description of change Add Attachment Delete Attachment View Attachment View Attachment		
F.3.c Biohazards		
If the use of biohazards is or will be different from the previous submission, provide a description and explanation of the difference(s).		
No Change or upload description of change Add Attachment Delete Attachment View Attachment View Attachment		
F.3.d Select Agents		
If the possession, use, or transfer of Select Agents is or will be different from that proposed in the previous submission, including any change in the select agent research location and/or the required level of biocontainment, provide a description and explanation of the differences. If the use of Select Agents was proposed in the previous submission but has not been approved by regulatory authorities, provide an explanation. If studies involving Select Agents are planned and were not part of the originally proposed research design, provide a description of the proposed use, possession, transfer, and research location as described in the competing application instructions.		
U.S. Select Agent Registry information: http://www.selectagents.gov/Select%20Agents%20and%20Toxins.html		

G. Special Reporting Requirements

G.1 Special NOA or FOA reporting requirements.

Select nothing to report or add attachment as needed. Attachments must be in PDF format; PDF file name must not contain spaces or special characters.

G.2-3 Not applicable to most awards




G.4 Human subjects

G.4.a Involvement of Human Subjects


If activities involving human subjects are planned at any time during the next budget period at the grantee organization or at any other project/performance site or collaborating institution, select **Yes**. Select **Yes** even if the project is exempt from the Regulations for the Protection of Human Subjects. Select **No** if activities involving human subjects are not planned at any time during the next budget period.

● Yes ○ No				
O Yes O No				
□E1 □E2 □E3 □E4 □E5 □E6				
○ Yes No				
○ Yes No				
G.4.b Inclusion Enrollment Data Please review the box below to determine if this project meets the definition of clinical research and requires the reporting of cumulative enrollment of subjects and the distribution of sex/gender, ethnicity and race. Click here for complete instructions about this requirement. Please contact the NIH Program Official [First Name] [Last Name] at email@email.com with any questions.				
Inclusion Enrollment				
This project does not require Inclusion Enrollment Reports. Please contact the NIH Program Official with questions.				
G.4.c ClinicalTrials.gov (?) Does this project include one or more applicable clinical trials that must be registered in ClinicalTrials.gov under FDAAA? Yes No If yes, provide the ClinicalTrials.gov identifier, NCT number (e.g., NCT00654321) for those trials.				

G.5 Human Subjects Education Requirement




G.6 Human Embryonic Stem Cells



G.7 Vertebrate Animals
If there are changes, edit as needed.

G.8 Project/Performance Sites If there are changes, edit as needed.



G.9 Foreign Component

Select No Foreign Component or provide information as needed.

G.9 Foreign Component
"Foreign component" is defined as significant scientific activity that was performed outside of the United States, either by the grantee or by a researcher employed by a foreign organization, whether or not grant funds were expended. The following grant-related activities are significant and must be reported:
 involvement of human subjects or research with live vertebrate animals; extensive foreign travel by grantee project staff to collect data, or conduct surveys or sampling activities; or any grantee activity that may have an impact on U.S. foreign policy.
Examples of other grant-related activities that <i>may</i> be significant are:
 collaborations with investigators at a foreign site anticipated to result in co-authorship; use of facilities or instrumentation at a foreign site; or receipt of financial support or resources from a foreign entity.
Foreign travel for consultation does not meet the definition of foreign component.
No foreign component
or provide the organization name, country, and description of each foreign component
Organization Name Country Please select a country ▼
Description of Foreign Component (Limit is 700 characters or approximately 1/4 of a page.)
Total remaining allowed limit is 700 characters. Add/New Clear


G.10 Estimated Unobligated Balance

Answer and provide information as required.

G.10 Estimated Unobligated Balance
G.10.a Is it anticipated that an estimated unobligated balance (including prior year carryover) will be greater than 25% of the current year's total approved budget? 🔘 Yes 🕒 No
The "total approved budget" equals the current fiscal year award authorization plus any approved carryover of funds from a prior year(s). The numerator equals the total amount available for carryover and the denominator equals the current year's total approved budget. If yes, provide the estimated unobligated balance.
G.10.b Provide an explanation for unobligated balance below (Limit is 700 characters or approximately 1/4 of a page.)
Total remaining allowed limit is 700 characters.
G.10.c If authorized to carryover the balance, provide a general description of how it is anticipated that the funds will be spent. To determine carryover authorization, see the Notice of Award (Limit is 1300 characters or approximately 1/2 of a page.)
Total remaining allowed limit is 1300 characters.

G.11 Program Income

Answer yes if program income is anticipated in the next budget period, and provide amount and source(s).




G.12 F&A Costs

Answer and enter explanation as needed.

G.12 F&A Costs	ı
	ı
Is there a change in performance sites that will affect F&A costs? Yes No	ı
If yes, provide an explanation below (Limit is 1300 characters or approximately 1/2 of a page.)	ı
	ı
	I
	ı
Total remaining allowed limit is 1300 characters.	ı
Save Cancel A Cover Page B Accomplishments C Products D Participants E Impact F Changes G Special Reporting Req H Budget	
	-1

H. Budget

Applicable to non-SNAP awards only.



Complete and Submit RPPR

Once complete, click on Manage eSNAP.

Click on the Check for Errors button. If there are any errors, they must be corrected. Be certain to save the changes.

Once there are no more errors, click the Route button to route to Contact Administrator in ORA (only required if 25% or more reduction of effort for Senior/Key Personnel) or Submit to submit directly to NIH.



If you do not have access to Submit to NIH directly, please contact or Contract Administrator and/or email oraneea@umd.edu to request this access.